{"id":440477,"date":"2010-03-17T15:47:00","date_gmt":"2010-03-17T19:47:00","guid":{"rendered":"e2249889-c78b-43e3-9643-b1d7d4aa587b:409108"},"modified":"2010-03-17T15:47:00","modified_gmt":"2010-03-17T19:47:00","slug":"paladin-labs-hits-52-week-high","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/440477","title":{"rendered":"Paladin Labs hits 52-week high"},"content":{"rendered":"<p>Paladin Labs Inc. had its biggest day in weeks on Wednesday, jumping almost 6% to a new 52-week high of $21.58.&nbsp;<\/p>\n<p>Late Tuesday night, the company announced that it has acquired a 34.99% ownership interest in Pharmaplan Ltd., a South African specialty pharma company, Paladin also committed to raising its ownership stake over time based on Pharmaplan&#39;s overall performance.  <\/p>\n<p>&quot;This is a significant transaction for the company towards expanding in an emerging market territory,&quot; said Maher Yaghi, Desjardins Securities analyst.&nbsp; <\/p>\n<p>&quot;We are encouraged by this opportunity given that the South African market provides the potential for respectable profit margins similar to what Paladin attains in Canada, but with stronger growth prospects.&quot;<\/p>\n<p>Mr. Yaghi reiterated his Buy recommendation on the stock and left his $21.30 price target unchanged. <\/p>\n<p>&quot;We have already included in our valuation for Paladin a $2.44\/share component that reflects the potential from acquisitions worth $75-million,&quot; he wrote.&nbsp; <\/p>\n<p>&quot;While we do not believe the 35% ownership interest to be worth more than $75-million, we will be reviewing our acquisition potential scenarios given the more aggressive stance by management demonstrated by this new venture.&quot;<\/p>\n<p><a href=\"mailto:dpett@nationalpost.com%20\">David Pett<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/network.nationalpost.com\/NP\/aggbug.aspx?PostID=409108\" width=\"1\" height=\"1\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paladin Labs Inc. had its biggest day in weeks on Wednesday, jumping almost 6% to a new 52-week high of $21.58.&nbsp; Late Tuesday night, the company announced that it has acquired a 34.99% ownership interest in Pharmaplan Ltd., a South African specialty pharma company, Paladin also committed to raising its ownership stake over time based [&hellip;]<\/p>\n","protected":false},"author":4060,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-440477","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/440477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/4060"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=440477"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/440477\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=440477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=440477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=440477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}